Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1992 1
1993 1
1995 1
1997 1
1999 1
2003 2
2005 1
2006 2
2007 6
2008 3
2009 7
2010 11
2011 13
2012 17
2013 18
2014 12
2015 19
2016 7
2017 5
2018 6
2019 10
2020 8
2021 4
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 25368271

145 results

Results by year

Filters applied: . Clear all
Page 1
A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
Uetake H, Yasuno M, Ishiguro M, Kameoka S, Shimada Y, Takahashi K, Watanabe T, Muro K, Baba H, Yamamoto J, Mizunuma N, Tamagawa H, Mochizuki I, Kinugasa Y, Kikuchi T, Sugihara K. Uetake H, et al. Ann Surg Oncol. 2015 Mar;22(3):908-15. doi: 10.1245/s10434-014-4094-7. Epub 2014 Dec 3. Ann Surg Oncol. 2015. PMID: 25465375 Clinical Trial.
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R. Gruenberger T, et al. Ann Oncol. 2015 Apr;26(4):702-708. doi: 10.1093/annonc/mdu580. Epub 2014 Dec 23. Ann Oncol. 2015. PMID: 25538173 Free article. Clinical Trial.
Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
Hatano E, Okuno M, Nakamura K, Ishii T, Seo S, Taura K, Yasuchika K, Yazawa T, Zaima M, Kanazawa A, Terajima H, Kaihara S, Adachi Y, Inoue N, Furumoto K, Manaka D, Tokka A, Furuyama H, Doi K, Hirose T, Horimatsu T, Hasegawa S, Matsumoto S, Sakai Y, Uemoto S. Hatano E, et al. J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):634-45. doi: 10.1002/jhbp.254. Epub 2015 Apr 29. J Hepatobiliary Pancreat Sci. 2015. PMID: 25926024 Clinical Trial.
Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
Takatsuki M, Tokunaga S, Uchida S, Sakoda M, Shirabe K, Beppu T, Emi Y, Oki E, Ueno S, Eguchi S, Akagi Y, Ogata Y, Baba H, Natsugoe S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Takatsuki M, et al. Eur J Surg Oncol. 2016 Feb;42(2):184-9. doi: 10.1016/j.ejso.2015.11.007. Epub 2015 Nov 22. Eur J Surg Oncol. 2016. PMID: 26683263 Free article. Clinical Trial.
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E. Schmoll HJ, et al. J Clin Oncol. 2012 Oct 10;30(29):3588-95. doi: 10.1200/JCO.2012.42.5355. Epub 2012 Sep 10. J Clin Oncol. 2012. PMID: 22965961 Clinical Trial.
145 results